Nuvation Bio Inc.
NUVB · NYSE
Analyst ratings
strong_buy · 6 ratings
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| July 7, 2026 | RBC Capital | Maintains | Outperform | $19.00 |
| July 7, 2026 | Truist Securities | Maintains | Buy | $13.00 |
| May 5, 2026 | RBC Capital | Reiterates | Outperform | $20.00 |
| May 5, 2026 | Wedbush | Reiterates | Outperform | $11.00 |
| May 5, 2026 | HC Wainwright & Co. | Reiterates | Buy | $17.00 |
| April 16, 2026 | Wedbush | Reiterates | Outperform | $11.00 |
| April 2, 2026 | Wedbush | Reiterates | Outperform | $11.00 |
| March 27, 2026 | Wedbush | Reiterates | Outperform | $11.00 |
| March 3, 2026 | UBS | Maintains | Neutral | $7.00 |
| March 3, 2026 | RBC Capital | Maintains | Outperform | $13.00 |
| February 10, 2026 | Wedbush | Reiterates | Outperform | $11.00 |
| January 21, 2026 | RBC Capital | Maintains | Outperform | $12.00 |
| January 12, 2026 | HC Wainwright & Co. | Maintains | Buy | $17.00 |
| December 11, 2025 | HC Wainwright & Co. | Maintains | Buy | $18.00 |
| December 1, 2025 | HC Wainwright & Co. | Reiterates | Buy | $10.00 |
| November 20, 2025 | Citizens | Maintains | Market Outperform | $10.00 |
| November 4, 2025 | RBC Capital | Maintains | Outperform | $8.00 |
| November 4, 2025 | Citizens | Maintains | Market Outperform | $8.00 |
| October 13, 2025 | Wedbush | Reiterates | Outperform | $6.00 |
| September 19, 2025 | HC Wainwright & Co. | Reiterates | Buy | $10.00 |
| September 8, 2025 | Wedbush | Reiterates | Outperform | $6.00 |
Clinical pipeline value and revenue sustainability
Nuvation Bio delivered a strong earnings beat, reporting $0.01 EPS versus an expected loss and $83.23 million in revenue versus the $66.22 million consensus estimate. RBC Capital maintained an Outperform rating with a $20 price target, citing continued interest in the ROS1 oncology market following GSK's acquisition of a competitor.
Despite the revenue beat, Nuvation Bio carries a deeply negative net margin of -102.06% and a negative return on equity of -44.10%. Analysts at Zacks Research downgraded the stock to 'strong sell,' and sell-side forecasts project a full-year EPS of -$0.39, signaling persistent profitability concerns.
Valuation and price target divergence
HC Wainwright and RBC Capital have reaffirmed buy-equivalent ratings with price targets of $17 and $20 respectively, reflecting confidence in Nuvation Bio's long-term oncology pipeline. The stock has delivered a remarkable 195% return over the prior year, suggesting the market has begun to price in pipeline optionality.
UBS cut its price target from $10 to $7 and assigned a neutral rating, while Weiss Ratings maintained a sell rating. The consensus average 12-month target of $12.50 masks enormous dispersion, with the stock trading at $5.55 and two of eleven covering analysts holding outright sell recommendations.
$250M convertible notes offering and dilution risk
The $250 million convertible notes offering strengthens Nuvation Bio's balance sheet, providing runway to advance its clinical programs. RBC Capital reiterated its Outperform rating after the announcement, and InvestingPro's fair value estimate of $5.67 suggests the stock is fairly valued at current levels, limiting downside risk from the financing.
The convertible notes offering introduces meaningful dilution risk, with the stock trading well below the conversion price. High implied volatility of 112% and an insider selling 50,000 shares in April signal uncertainty. The high-risk technical profile and weak SMR rating reflect an unprofitable business model that may struggle to service new debt obligations.